Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04872608
Other study ID # 21-194
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date September 9, 2021
Est. completion date April 25, 2023

Study information

Verified date April 2023
Source Memorial Sloan Kettering Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The researchers are doing this study to find out whether the study drug onapristone ER, combined with the standard treatment for your cancer (letrozole and palbociclib), is a safe treatment for people who have metastatic or unresectable ER+/PR+/HER2- breast cancer. The researchers will test different doses of the study drug to find the highest dose that causes few or mild side effects.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date April 25, 2023
Est. primary completion date April 25, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed ER+, PR+, HER2- metastatic or unresectable breast cancer - PR positivity is defined as =1% expression by immunohistochemistry (IHC) on fresh or archival tumor tissue - Tissue samples obtained, stained, and interpreted outside of MSKCC will be accepted - Those patients who do not have adequate/accessible archival tissue available and for whom biopsy is not a significant risk procedure may be required to consent to pretreatment biopsy - Completed at least 6 months (+/- 4 weeks) of first-line letrozole/palbociclib without radiological progression or unresolved toxicity °Patients who underwent dose reduction of palbociclib to 100mg daily or 75mg daily will be eligible if: 1. The dose reduction was implemented =4 weeks prior to enrollment 2. Patients have demonstrated resolution of all acute toxic effects of prior therapy to NCI CTCAE (Version 5.0) Grade = 1 - ctDNA-positive, defined as: °Presence of a tumor-derived somatic mutation in the peripheral blood using the MSK-ACCESS assay after 6 months of letrozole/palbociclib (+/- 4 weeks); at least one mutation should have avariant allele fraction of = 0.5% - Completed MSK IMPACT testing from primary or metastatic tissue - Radiologically evaluable or measurable disease per RECIST Version 1.1 - Age = 18 years - Pre-menopausal patients are eligible as long as they are on LHRH agonist for at least four weeks prior to starting trial therapy and commit to continue LHRH agonist for as long as patient is receiving trial therapy or medical contraindications arise. - Eastern Cooperative Oncology Group Performance Status (ECOG) of 1 or Karnofsky Performance Status (KPS) of = 70% - Women of child-bearing potential: - Must have a negative pregnancy test within 14 days prior to commencement of study treatment - Agreement to remain abstinent (refrain from heterosexual intercourse) or use nonhormonal contraceptive methods with a failure rate of <1% per year during the treatment period and for 120 days after the last dose and agreement to refrain from donating eggs during this same period - Note: for women with therapy-induced amenorrhea, baseline measurements of FSH and/or estradiol are needed to ensure menopausal status. - Adequate hematologic and organ function demonstrated within 14 days prior to initiation of study treatment, defined by the following: - Absolute neutrophil count = 1.2K/ µL - Hemoglobin = 9 g/dL - Platelet count = 100,000/ µL - Total bilirubin = 1.5 x ULN - Serum albumin = 2.5 g/dL - AST and ALT = 2.5 x ULN - Serum creatinine = 1.5 x ULN or creatinine clearance = 50 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation - INR < 1.5 x ULN and aPTT < 1.5 x ULN °For patients requiring anticoagulation therapy with warfarin, a stable INR between 2-3 is required. If anticoagulation is required for a prosthetic heart valve, then stable INR between 2.5-3.5 is permitted. - At least 4 weeks post-op from any major surgical procedure - Patients with asymptomatic brain metastases which have been treated with surgery or radiation and demonstrate stability for = 3 months will be allowed - Able to swallow tablets whole, without crushing Exclusion Criteria: - Radiologic disease progression while on treatment with letrozole and palbociclib in the first line prior to enrollment - History of another invasive malignancy (other than non-melanoma skin cancer or curatively treated in situ carcinoma) with evidence of disease within the past 3 years - Any psychological, familial, sociological or geographic condition that would potentially hinder compliance with the study protocol - Known untreated or symptomatic brain metastasis - Uncontrolled hypertension (systolic BP = 160 mmHg or diastolic BP = 95mmHg) despite medical treatment. Patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment. - Clinically significant heart disease as evidenced by myocardial infarction or arterial thrombotic event within the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction measurement of < 50% at baseline - Screening ECG with rate-corrected (using Friderica's correction) QT interval (QTcF) of >480 msec or a history of cardiac arrythmias - Refractory nausea and vomiting, requirement for parenteral hydration and/or nutrition, drainage gastrostomy tube, malabsorption, external biliary shunt, or significant small bowel resection that would preclude adequate study drug absorption - Is pregnant or breastfeeding, and/or expecting to conceive within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment. - Current use of estrogen or progesterone products including intrauterine and implantable contraceptive devices. - Anticipated or ongoing administration of anti-cancer therapies other than those administered in this study - Active Hepatitis B (HBsAg positive or hepatitis B virus DNA=1×10^3 copy/ml) or Hepatitis C (e.g., HCV RNA [qualitative] is detected). - Use of any prescription medication during the prior 28 days of first onapristone dosing that the investigator judges is likely to interfere with onapristone activity; specifically, strong inhibitors or inducers, or sensitive substrates of cytochrome P450 CYP3A4.

Study Design


Intervention

Drug:
Letrozole
Letrozole will be given daily on days 1-28.
Palbociclib
Palbociclib will be given daily on days 1-21 and held on days 22-28, as per standard FDA-approved dosing guidelines.
Onapristone ER
Onapristone will be given daily on days 1-28.

Locations

Country Name City State
United States Memorial Sloan Kettering Westchester (All Protocol Activities) Harrison New York

Sponsors (2)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center Context Therapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary recommended phase 2 dose (RP2D) of onapristone ER The RP2D/MTD will be defined as the dose level at which a dose limiting toxicity (DLT) occurs in at most 1 out of 6 patients in that dose cohort. 1 year
See also
  Status Clinical Trial Phase
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Completed NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer Phase 2
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Recruiting NCT03368729 - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Completed NCT04103853 - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer Phase 1
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Active, not recruiting NCT03147287 - Palbociclib After CDK and Endocrine Therapy (PACE) Phase 2
Not yet recruiting NCT06062498 - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT04095390 - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Phase 2
Active, not recruiting NCT04432454 - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Recruiting NCT05744375 - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Phase 2
Completed NCT02924883 - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy Phase 2
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Completed NCT01942135 - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Phase 3
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT01401959 - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Phase 2
Terminated NCT04720664 - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer Phase 2
Withdrawn NCT05191004 - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC Phase 1/Phase 2